Hapten-carrier conjugates for use in drug abuse therapy and methods for preparation of same
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
1 - 87 . (canceled)
88 . A method for inducing an immune response in a subject in need thereof, the method comprising administering to a subject an effective amount of a composition comprising a hapten-carrier conjugate comprising at least one hapten conjugated to a carrier, wherein the hapten is cocaine, a cocaine metabolite or a cocaine derivative and the carrier is a bacterial toxin, a product of a bacterial toxin, a subviral, lectin, an allergen, a fragment of an allergen, a malarial protein antigen, an artificial multi-antigenic peptide, or a modification, analog or a derivative thereof.
89 . A method for preventing and/or treating cocaine addiction, the method comprising administering to a subject in need thereof an effective amount of a composition comprising a hapten-carrier conjugate comprising at least one hapten conjugated to a carrier, wherein the hapten is cocaine, a cocaine metabolite or a cocaine derivative and the carrier is a bacterial toxin, a product of a bacterial toxin, a subviral, lectin, an allergen, a fragment of an allergen, a malarial protein antigen, an artificial multi-antigenic peptide, or a modification, analog or a derivative thereof.
90 . The method of claim 88 or 89 , wherein the carrier is cholera toxin B, diphtheria toxin, tetanus toxoid, pertussis toxin, filamentous hemagglutinin, Shiga toxin, pseudomonas exotoxin, ricin B subunit, abrin, sweet pea lectin, retrovirus nucleoprotein, rabies nucleoprotein, tobacco mosaic virus, cauliflower mosaic virus, vesicular stomatitis virus-nucleocapsid protein, poxvirus subunit, Semliki forest virus vector or yeast virus-like particle.
91 . The method of claim 90 , wherein the carrier is a bacterial toxin or a product of a bacterial toxin
92 . The method of claim 91 , wherein the carrier is cholera toxin B, diphtheria toxin, tetanus toxoid, pertussis toxin, filamentous hemagglutinin, Shiga toxin, or pseudomonas exotoxin.
93 . The method of claim 92 , wherein carrier is cholera toxin B.
94 . The method of claim 93 , wherein carrier is a recombinant cholera toxin B.
95 . The method of claim 88 wherein the hapten-carrier conjugate is of formula I:
and wherein Q is a cholera toxin B (CTB) carrier.
96 . The method of claim 89 wherein the hapten-carrier conjugate is of formula I:
and wherein Q is a cholera toxin B (CTB) carrier.
97 . The method of claim 89 or 96 further comprising administering another therapy.
98 . The method of claim 88 , 89 , 95 or 96 , wherein the composition is administered parenterally, orally, intranasally, topically, dermally or intratracheally.
99 . The method of claim 88 , 89 , 95 , or 96 , wherein the subject is a mammal.
100 . The method of claim 99 , wherein the subject is a human.
101 . The method of claim 88 , 89 , 95 , or 96 , wherein the composition further comprises an adjuvant.
102 . The method of claim 101 , wherein the adjuvant is alum, MF-59 or RIBI adjuvant.
103 . The method of claim 102 , wherein the adjuvant is alum.
104 . The method of claim 103 , wherein the adjuvant is aluminum hydroxide.